704 related articles for article (PubMed ID: 19549529)
1. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
Araki Y; Okamura S; Hussain SP; Nagashima M; He P; Shiseki M; Miura K; Harris CC
Cancer Res; 2003 Feb; 63(3):728-34. PubMed ID: 12566320
[TBL] [Abstract][Full Text] [Related]
3. BCL9-2 promotes early stages of intestinal tumor progression.
Brembeck FH; Wiese M; Zatula N; Grigoryan T; Dai Y; Fritzmann J; Birchmeier W
Gastroenterology; 2011 Oct; 141(4):1359-70, 1370.e1-3. PubMed ID: 21703997
[TBL] [Abstract][Full Text] [Related]
4. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
5. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
6. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Easwaran V; Lee SH; Inge L; Guo L; Goldbeck C; Garrett E; Wiesmann M; Garcia PD; Fuller JH; Chan V; Randazzo F; Gundel R; Warren RS; Escobedo J; Aukerman SL; Taylor RN; Fantl WJ
Cancer Res; 2003 Jun; 63(12):3145-53. PubMed ID: 12810642
[TBL] [Abstract][Full Text] [Related]
7. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
Takahashi M; Nakamura Y; Obama K; Furukawa Y
Int J Oncol; 2005 Dec; 27(6):1483-7. PubMed ID: 16273202
[TBL] [Abstract][Full Text] [Related]
8. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
[TBL] [Abstract][Full Text] [Related]
9. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice.
Musteanu M; Blaas L; Mair M; Schlederer M; Bilban M; Tauber S; Esterbauer H; Mueller M; Casanova E; Kenner L; Poli V; Eferl R
Gastroenterology; 2010 Mar; 138(3):1003-11.e1-5. PubMed ID: 19962983
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling inside the nucleus.
Shitashige M; Hirohashi S; Yamada T
Cancer Sci; 2008 Apr; 99(4):631-7. PubMed ID: 18177486
[TBL] [Abstract][Full Text] [Related]
11. Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling.
Samuel MS; Suzuki H; Buchert M; Putoczki TL; Tebbutt NC; Lundgren-May T; Christou A; Inglese M; Toyota M; Heath JK; Ward RL; Waring PM; Ernst M
Gastroenterology; 2009 Sep; 137(3):902-13, 913.e1-11. PubMed ID: 19454286
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors.
Reichling T; Goss KH; Carson DJ; Holdcraft RW; Ley-Ebert C; Witte D; Aronow BJ; Groden J
Cancer Res; 2005 Jan; 65(1):166-76. PubMed ID: 15665292
[TBL] [Abstract][Full Text] [Related]
13. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
14. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.
Aoki K; Aoki M; Sugai M; Harada N; Miyoshi H; Tsukamoto T; Mizoshita T; Tatematsu M; Seno H; Chiba T; Oshima M; Hsieh CL; Taketo MM
Oncogene; 2007 May; 26(24):3511-20. PubMed ID: 17160019
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of APC promoter 1A is associated with moderate activation of Wnt signalling pathway in a subset of colorectal serrated adenomas.
Fu X; Li J; Li K; Tian X; Zhang Y
Histopathology; 2009 Nov; 55(5):554-63. PubMed ID: 19912361
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer and genetic alterations in the Wnt pathway.
Segditsas S; Tomlinson I
Oncogene; 2006 Dec; 25(57):7531-7. PubMed ID: 17143297
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Shattuck-Brandt RL; Lamps LW; Heppner Goss KJ; DuBois RN; Matrisian LM
Mol Carcinog; 1999 Mar; 24(3):177-87. PubMed ID: 10204802
[TBL] [Abstract][Full Text] [Related]
20. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.
Green DW; Roh H; Pippin JA; Drebin JA
J Surg Res; 2001 Nov; 101(1):16-20. PubMed ID: 11676549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
